Salt Inducible Kinase Inhibitors Patent Granted to General Hospital Corporation
Summary
USPTO granted patent US12600719B2 to General Hospital Corporation covering salt inducible kinase (SIK) inhibitor compounds and pharmaceutical compositions. Inventors Marc Nathan Wein and William J. Greenlee filed the application on August 5, 2021. The patent contains 20 claims under CPC classification C07D 471/04.
What changed
USPTO issued patent US12600719B2 for salt inducible kinase (SIK) inhibitor compounds and associated pharmaceutical compositions. The patent grants exclusive rights to General Hospital Corporation for methods of treating diseases linked to abnormal SIK expression or activity.
Pharmaceutical companies, biotechnology firms, and research institutions developing kinase-targeted therapies should review this patent to assess potential licensing requirements or design-around strategies. Generic and biosimilar manufacturers may need to evaluate Freedom to Operate implications when developing competing compounds.
What to do next
- Monitor patent portfolio for licensing opportunities
- Review patent claims for potential infringement
- Contact General Hospital Corporation licensing office for commercialization inquiries
Archived snapshot
Apr 15, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Salt inducible kinase inhibitors
Grant US12600719B2 Kind: B2 Apr 14, 2026
Assignee
The General Hospital Corporation
Inventors
Marc Nathan Wein, William J. Greenlee
Abstract
The present application provides compounds that modulate the activity of one or more salt inducible kinases (SIKs). Pharmaceutical composition and methods of treating diseases associated with abnormal expression and/or activity of one or more SIKs are also provided.
CPC Classifications
C07D 471/04
Filing Date
2021-08-05
Application No.
18019527
Claims
20
Related changes
Get daily alerts for USPTO Patent Grants - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Organic Chemistry (C07D) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.